ARTICLE | Company News
GSK gains Zejula, immuno-oncology portfolio in $5.1B Tesaro takeout
December 7, 2018 6:04 PM UTC
Although it's inheriting a portfolio of cancer compounds from Tesaro Inc. (NASDAQ:TSRO) that fall squarely into competitive areas, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) expects to transform the candidates, including Zejula niraparib, into best-in-class therapies under Hal Barron's R&D leadership.
The pharma is acquiring Tesaro for $75 per share in a deal the partners say values Tesaro at $5.1 billion including debt. The price is a 62% premium to Tesaro’s close of $46.38 on Nov. 30, before the deal was announced...